Journal Watch - Roxadustat
-
PD, Anemia, and Roxadustat
A systematic review and meta-analysis of eight studies (n=607) evaluated the efficacy and safety of Roxadustat in PD, finding that the drug significantly increased hemoglobin and TIBC and reduced hepcidin. Ferritin, TSAT, cholesterol and triglycerides, and diastolic blood pressure were not significantly affected.
Read the abstract » | (added 2026-06-17)
Tags: Roxadustat
-
New Nomogram Predicts Roxadustat Treatment Failure in Anemic PD Patients
A retrospective analysis of 204 anemic PD patients from 2019 to 2023 was used to construct a predictive nomogram of Roxadustat success. Duration of PD, serum transferrin, cardiovascular comorbidities and stains were significant predictors. The nomogram was more predictive at 12 months than at 6 months.
Read the abstract » | (added 2024-04-12)
Tags: Roxadustat, HIF inhibitor, Treatment Failure, Anemia, PD